ERBB2 and breast carcinoma: In a phase I/II trial (NCT00841399/NCT00584789), E75 vaccine was well tolerated and reduced recurrence rates (5-year DFS: 89.7% vs 80.2%; P = 0.08) in breast cancer patients whose tumors expressed any level of HER2 (IHC 1–3+).